Announcements

Conference: Nutrients 2026—Clinical Nutrition: From Research to Practice
Date: 22–24 October 2026, CEST, Barcelona, Spain
Website: https://sciforum.net/event/Nutrients2026

We cordially invite you to attend and submit an abstract to this event, organized by MDPI’s Nutrients (ISSN 2072-6643, Impact Factor: 5.8, CiteScore: 10.2). It will take place from 22 to 24 October 2026, CEST, at UAB Casa Convalescencia, Barcelona, Spain.

Conference Chairs:

• Prof. Dr. Maria Luz Fernandez, University of Connecticut, USA;
• Prof. Dr. Lluis Serra Majem, University of Las Palmas de Gran Canaria, Spain;
• Dr. Francisco Jose Perez Cano, University of Barcelona, Spain.

Topics of Interest:
S1. Personalized nutrition based on diet–gene interactions;
S2. Innovations in clinical nutrition;
S3. Novel dietary recommendations for specific chronic diseases;
S4. Understanding the role of microbiota in clinical practice;
S5. The potential role of AI in clinical practice;
S6. Lifestyle and prevention of chronic diseases.

Plenary Speaker Announcement:
We are honored to have Dr. Carlo La Vechia, from the University of Milan ("La Statale"), Italy, as Nutrients 2026 Plenary Speaker for Session 6: Lifestyle and prevention of chronic diseases.

Other renowned researchers from internationally prestigious universities and institutes, including Yale School of Public Health, University of Connecticut, Qatar University, Icahn Medical School of Mount Sinai, and many more, are contributing with us as keynote speakers and scientific committee members.

To view all contributing researchers, please click the following link:
https://sciforum.net/event/Nutrients2026?section=#event_chairs.

Academic Supporters:
Nutrients 2026 is currently supported by and partnered with esteemed universities, institutes, and societies.

To view all supporting organizations and partners, please click on the following link:
https://sciforum.net/event/Nutrients2026?section=#sup_org.

Important Dates:
Deadline for abstract submissions: 24 July 2026;
Notification of acceptance: 14 August 2026;
Deadline for early bird registration: 28 August 2026;
Deadline for covering author registration: 28 August 2026.

Guide for Authors
To submit your abstract, please click on the following link: https://sciforum.net/user/submission/create/1496.

To register for the event, please click on the following link: https://sciforum.net/event/Nutrients2026?section=#registration.

For details regarding abstract submission, poster and slide submission, and publication opportunities, you may refer to the “Instructions for Authors” section below: https://sciforum.net/event/Nutrients2026?section=#instructions.

For any enquiries regarding the event, please contact nutrients2026@mdpi.com.

We look forward to seeing you at Nutrients 2026.

Conference: Nutrients 2026—Clinical Nutrition: From Research to Practice
Date: 22–24 October 2026, CEST, Barcelona, Spain
Website: https://sciforum.net/event/Nutrients2026

We cordially invite you to attend this event organized by MDPI’s Nutrients (ISSN: 2072-6643, impact factor: 5.0, CiteScore: 9.1). It will take place on 22 to 24 October 2026, CEST, in Barcelona, Spain.

Conference Chairs:

• Prof. Dr. Maria Luz Fernandez, University of Connecticut, USA;
• Prof. Dr. Lluis Serra Majem, University of Las Palmas de Gran Canaria, Spain.

The Topics of Interest:

S1. Personalized nutrition based on diet–gene interactions;
S2. Innovations in clinical nutrition;
S3. Novel dietary recommendations for specific chronic diseases;
S4. Understanding the role of microbiota in clinical practice;
S5. The potential role of AI in clinical practice;
S6. Lifestyle and prevention of chronic diseases.

Important Dates

Deadline for abstract submissions: 24 June 2026;
Notification of acceptance: 20 July 2026;
Deadline for early bird registration: 24 July 2026;
Deadline for covering author registration: 24 July 2026.

Guide for Authors

To submit your abstract, please click on the following link: https://sciforum.net/user/submission/create/1496.

To register for the event, please click on the following link: https://sciforum.net/event/Nutrients2026?section=#registration.

For details regarding abstract submission, poster and slide submission, and publication opportunities, you may refer to the “Instructions for Authors” section below: https://sciforum.net/event/Nutrients2026?section=#instructions.

For any enquiries regarding the event, please contact nutrients2026@mdpi.com.

We look forward to seeing you at Nutrients 2026.

A range of MDPI journals will be attending International Congress Center Messe München in Munich, Germany from 28 to 31 August 2026.

Furthermore, 2026 marks MDPI’s third year of partnering with ESC Congress. Centered on the theme “Spotlight on Artificial Intelligence”, the conference explores AI as an auxiliary clinical tool that improves accuracy, workflow speed and patient safety. More than 32,000 delegates joined last year’s event, and MDPI secured 122 valuable contacts on-site.

The following open access journals will be represented at the ESC Congress 2026:

• JCDD;
• JCM;
• Antioxidants;
• Cardiogenetics;
• Cardiovascular Medicine;
• Hearts;
• IJERPH;
• Medicina;
• AI;
• Biomedicines;
• Clinics and Practice;
• EJIHPE;
• JPM;
• JVD;
• Tomography.

If you are planning to attend the above conference, please do not hesitate to drop by our booth and start a conversation with us; we look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.escardio.org/Congresses-Events/ESC-Congress# or contact the Journal of Cardiovascular Development and Disease Editorial Office at jcdd@mdpi.com.

We are pleased to announce that Prof. Dr. Ming Ma has been appointed Section Editor-in-Chief of the “Biomedical Engineering and Materials” Section in Biomedicines (ISSN 2227-9059).

Name: Prof. Dr. Ming Ma
Homepage: https://www.sic.cas.cn/sourcedb_sic_cas/zw/rck/202312/t20231211_6911679.html
Affiliation: Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China
Research interests: microfluidic synthesis; nanomedicine; high-throughput experimentation technologies; drug delivery; stem cell therapy

Prof. Dr. Ming Ma received his PhD degree from the University of Chinese Academy of Sciences in 2013. He is currently a full professor at the Shanghai Institute of Ceramics, CAS. His research interests include micro-/nano-scale functional particles for biomedical applications, as well as microfluidic synthesis and high-throughput experimental techniques. He has published approximately 80 peer-reviewed papers in prominent international journals. Additionally, as an Editorial Board Member of Biomedicines, he has been actively involved in the manuscript review process for over three years. Recently, he has also participated in the construction of the Biomedical Materials Data Resource Hub of China.

The following is a short Q&A with Prof. Dr. Ming Ma, who shared his vision for the journal with us as well as his views on the current state of the field:

1. What about the journal made you want to take on the role of Section Editor-in-Chief?
Biomedicines is a highly international platform that brings together research achievements of scientists from around the world. The publishers and editors have a clear vision to significantly improve the academic quality of manuscripts and rapidly disseminate the latest high-quality research through Biomedicines in the future. I am delighted to work with them to enhance the journal's quality and visibility.

2. What is your vision for the journal?
In the future, the Editorial Board of the “Biomedical Engineering and Materials” Section of Biomedicines will place particular emphasis on data authenticity, result completeness, reproducibility, and the innovation and scientific value of research findings when evaluating submissions. By raising the manuscript selection standards, I believe that within one to two years, Biomedicines will become a highly reputable and internationally recognized academic journal that researchers can trust.

3. What do you think of the development of open access in the publishing field?
Open access promotes rapid global sharing of scientific knowledge and enhances research accessibility for all scholars. However, article processing charges should be reasonable to minimize the financial burden on authors.

4. What does the future of this field of research look like?
Biomedical engineering and materials is an important scientific field that is closely related to human health and survival. In the future, this field will continue to produce numerous major theoretical and technological breakthroughs, thereby benefiting all of humanity.

5. Do you have any suggestions for young researchers in this field?
We encourage early-career scientists to pursue creative, challenging research that promotes the healthy development of the field. Even if the performance of the developed biomedical materials at the time of publication does not fully meet all the high-level expectations originally set, such work is still welcome in our journal as long as it offers significant reference value and inspiration from a new perspective.

We are pleased to share that Biomedicines (ISSN 2227-9059) was awarded an increased Impact Factor of 4.5 in the 2025 Journal Citation Reports™ released by Clarivate™ in June 2026.

Additionally, according to data released by Scopus (Elsevier), Biomedicines received an increased CiteScore of 7.8, an increase of 14.7% compared with the 2024 metric.

Biomedicines’ CiteScore ranks as follows:

• Q1 (57 out of 466) in the “Medicine (miscellaneous)” category;
• Q1 (39 out of 223) in the “General Biochemistry, Genetics and Molecular Biology” category.

The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.

Biomedicines Editorial Office

We are pleased to announce that Dr. Brian Reed has been recognized as one of the Exceptional Reviewers of Biomedicines (ISSN 2227-9059).

This program was established to recognize and honor scholars who have consistently provided outstanding review reports for our journal. Dedicated to advancing rigorous research and encouraging the exchange of knowledge, Biomedicines acknowledges the vital contributions of our reviewers in upholding the quality, credibility, and integrity of the articles we publish.

Dr. Brian Reed is a tenure-track assistant professor of chemistry and biology at the Department of Biology, Chemistry, Earth & Environmental Sciences at Molloy University on Long Island, NY. Prior to this, he spent over two decades at Rockefeller University in the Laboratory of the Biology of Addictive Diseases, led by the late Dr. Mary Jeanne Kreek. He initially joined her lab as a postdoctoral fellow from 2001 to 2006—holding a co-appointment in Dr. Brian Chait’s Laboratory of Mass Spectrometry and Gaseous Ion Chemistry—and subsequently continued his work there as a senior scientist, focusing on the role of the endogenous opioid system in substance use disorders.

Read our interview with Dr. Reed below:

1. Can you share your current research direction and latest progress?
My current research at Molloy University investigates the endogenous opioid system using diverse cell culture disease models. One of my primary projects focuses on elucidating the mechanisms behind kappa opioid receptor agonist-induced remyelination. Additionally, in an exciting new collaboration with my Molloy colleague, Dr. Jodi Evans, we are investigating the co-regulation of the melanocortin and opioid systems in cartilage preservation using cell culture models of osteoarthritis.

2. Could you please share your feelings about winning the award? What does this award mean for your academic career?
As I approach the tenure application process, having this award for my portfolio is fantastic. Peer review is a vital cornerstone of the scientific community, yet it is traditionally an anonymous and thankless task. Simply logging a review doesn't capture whether the feedback was thorough or constructive. Because this work is hidden, it can be difficult to properly document for tenure evaluation. This award validates my rigorous approach to peer review and provides tangible, high-profile evidence of my service to the field.

3. What role do you think reviewers play in the process of paper publication?
Reviewers are critical not just for vetting manuscripts, but for elevating them. While scientific rigor occasionally requires us to recommend rejection, I believe our most valuable contribution is helping authors refine their work. The iterative review process—where exciting findings are shaped into an even clearer, more impactful communication for the scientific community—is easily the most rewarding aspect of peer review.

4. How do you balance the comprehensiveness and efficiency of the review process? Can you share some specific methods or principles for reviewing?
I split my review into two distinct phases to balance depth and speed. First, I print the manuscript and read it in a single sitting—often during my morning train commute—marking up the margins and circling references that require a closer look. Second, back at my computer with reference databases open, I systematically address my margin notes, verify literature data, and draft my formal comments. Going through the paper twice in this manner ensures I don’t miss macro-level narrative flaws or micro-level technical issues.

5. In your opinion, what key qualities should an excellent manuscript have? From what perspectives will you help authors improve the quality of their papers?
An excellent manuscript must be well-written and clearly contextualize its findings within the current state of the field. Technically, it requires robust, highly detailed methodology and meticulously organized figures that allow readers to easily discern relevant details. Finally, the literature cited must be up-to-date and relevant. When reviewing, I actively provide feedback across all of these dimensions to help authors maximize their paper’s clarity and impact.

6. How do you hope that journals and publishers can further support the work of reviewers?
I was pleasantly surprised by this recognition. I think more publishers should adopt reviewer awards to honor this critical service. Beyond recognition, publishers should continue to balance rapid publication timelines with a realistic appreciation for reviewers' busy schedules. Lastly, offering article processing charge (APC) waivers or discounts to active reviewers is a highly practical and appreciated way to reciprocate our time and effort.

7. Please briefly describe your experience with our services and journals so far?
I have had an excellent experience with MDPI as both an author and a reviewer. The editorial process is highly efficient, turnaround times are swift, and communication with the editorial staff is always professional and pleasant.

We are pleased to announce that Prof. Dr. Martin Christian Michel has been recognized as one of the Exceptional Reviewers of Biomedicines (ISSN 2227-9059).

This program was established to recognize and honor scholars who have consistently provided outstanding review reports for our journal. Dedicated to advancing rigorous research and encouraging the exchange of knowledge, Biomedicines acknowledges the vital contributions of our reviewers in upholding the quality, credibility, and integrity of the articles we publish.

Prof. Dr. Martin Christian Michel is a physician-scientist focusing on the experimental and clinical pharmacology of the urogenital and cardiovascular systems.

Read our interview with Prof. Dr. Michel below:

1. Can you share your current research direction and latest progress?
I’m studying the effects of diabetes and anti-diabetic treatments on the urinary bladder and heart.

2. What role do you think reviewers play in the process of paper publication?
Reviewers are key to the quality and integrity of scientific publishing. This is particularly important as we unfortunately see an increasing number of fake papers generated by large language models. I’m happy to see that some publishers reward reviewer activity, e.g., with credits toward publishing charges.

3. How do you balance the comprehensiveness and efficiency of review? Can you share some specific methods or principles for reviewing?
I view the role of a reviewer as someone who advises the journal editor on the suitability of a manuscript based on its quality. However, it is equally important to assist authors in generating the best possible manuscript based on their data. This can lead to a large number of comments (20 or more) in some cases. Importantly, reviewer comments should always be constructive and not impose a personal opinion on others.

4. In your opinion, what key qualities should an excellent manuscript have? From what perspectives will you help authors improve the quality of their papers?
Evidence from the past 15 years shows that at least half of all reported research findings in the experimental life sciences cannot be reproduced. A good manuscript should address a relevant question by providing robust data related to a clearly defined research question. Robust data are based on pre-specified (preferably even pre-registered) study protocols involving randomization and blinding as far as feasible.

5. How do you hope that journals and publishers can further support reviewers’ work?
I consider checklists for authors a useful tool to facilitate the work of reviewers. This should not be based on boxes to tick (“did you”) but rather on asking specifically on which page of a manuscript certain things were addressed. Good examples of this are the checklists from the ARRIVE 2.0 guidelines and journals such as Diabetologia.

6. Please briefly describe your experience with our services and journals so far.
A major strength of Biomedicines and other MDPI journals from the authors' point of view is a fast turnaround. However, this can impose tight deadlines for reviewers. This is fine when this is clearly communicated at the time of primary submission. It can create problems for reviewers for revisions as they arrive at unpredictable moments when a reviewer may have a very full agenda.

To further develop Biomedicines (ISSN 2227-9059), under the guidance of our Section Editor-in-Chief, Prof. Dr. Jun Lu, the journal has updated and revised the scope of its Section “Drug Discovery, Development and Delivery”. The original Section Information and the updated version are listed below.

Section Information (new version):

"This Section publishes original and innovative scientific papers, as well as review papers. It is organized into topics mainly covering drug discovery, drug design, basic and clinical pharmacology, formulation and delivery, toxicology, and natural products research. Studies on substances obtained from natural sources, as well as their synthetic derivatives, are fully within the Section’s scope, provided that the compounds are chemically well defined. For research involving complex natural product mixtures, a suitable level of analytical characterization—such as through HPLC, MS, LC–MS, HPLC–MS, or NMR—is expected. In addition to the identification, chemistry, or analytical studies, manuscripts should also include in vitro and/or in vivo testing. Moreover, authors are encouraged to explore and discuss the cellular or molecular mechanisms of the natural compounds or characterized extracts."

Section Information (old version):

"This Section publishes original and innovative scientific papers, as well as comprehensive review papers. It is organized into topics mainly covering drug discovery, drug design, basic and clinical pharmacology, formulation and delivery, and toxicology."

For more detailed information, please visit the following link: https://www.mdpi.com/journal/biomedicines/sections/Drug_Discovery.

Biomedicines Editorial Office

The Korean Society of Medical Oncology (KSMO) has been committed to advancing clinical oncology and improving patient care through multidisciplinary collaboration. As one of the leading academic societies in Asia, the KSMO continues to foster excellence in cancer research, education, and professional development. KSMO 2026 will provide a stimulating forum to share scientific breakthroughs and practical clinical insights. Under the theme “Advancing Cancer Care, Restoring Hope and Lives”, the program is designed to highlight the latest evidence and innovations, helping bridge research and practice to improve patient outcomes.

About the media partner: Biomedicines

Biomedicines is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research on naturally derived biomedicines. Topics include pathogenesis mechanisms of diseases; translational medical research; clinical studies and applications; and novel targets in various therapeutic areas, such as oncology, cardiovascular, vascular, hematology, neurology, etc. As the media partner of KSMO 2026, Biomedicines will feature conference highlights, research spotlights, and author opportunities for attendees and the oncology research community within the broader field of biomedicines.

We look forward to seeing you at KSMO 2026!